A Randomized Phase II Study of AGS‐16C3F Versus Axitinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma

Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2019) Bernard Escudier et al.   ANNALS OF ONCOLOGY

The Interplay between Inflammation, Anti-Angiogenic Agents, and Immune Checkpoint Inhibitors: Perspectives for Renal Cell Cancer Treatment

(2019) Nicole Brighi et al.   Cancers

Phase 1 Trials of anti-ENPP3 antibody drug conjugates in advanced refractory renal cell carcinomas

(2018) John A Thompson et al.   CLINICAL CANCER RESEARCH

Systemic Therapy for Metastatic Renal-Cell Carcinoma

(2017) Toni K. Choueiri et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates

(2016) Heather Donaghy   mAbs

Mechanisms of Resistance to Antibody–Drug Conjugates

(2016) Frank Loganzo et al.   MOLECULAR CANCER THERAPEUTICS

Ocular Adverse Events Associated with Antibody–Drug Conjugates in Human Clinical Trials

(2015) Joshua Seth Eaton et al.   JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS

Evaluating the safety and efficacy of axitinib in the treatment of advanced renal cell carcinoma

(2015) Orvar Gunnarsson et al.   Cancer Management and Research

Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial

(2013) Robert J Motzer et al.   LANCET ONCOLOGY

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial

(2011) Brian I Rini et al.   LANCET

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER